ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

07 نوفمبر 2024 16:02:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

07 نوفمبر 2024 10:00:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 نوفمبر 2024 09:10:30 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

04 نوفمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

30 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

29 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

30 سبتمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

26 سبتمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

08 أغسطس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 

07 أغسطس 2024 16:02:54 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

31 يوليو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

01 يوليو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20 يونيو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

23 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

13 مايو 2024 16:47:42 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

13 مايو 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06 مايو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Announces Q2 Investor Conference Participation

09 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

14 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire